Gan & Lee Pharmaceuticals begins US Phase 2 trial of bofanglutide for obesity and weight management
Gan & Lee Pharmaceuticals (Shanghai Stock Exchange: 603087) has initiated its Phase 2 clinical trial of bofanglutide (GZR18) injection, with the first participant successfully dosed ... Read More
Gan & Lee gets EMA orphan drug status for GLR2007 in glioma
Gan & Lee Pharmaceuticals has been granted orphan drug designation for GLR2007 from the European Medicine Agency (EMA) for the treatment of glioma, a type ... Read More
Gan & Lee gets FDA orphan drug status for GLR2007 in malignant glioma
Gan & Lee Pharmaceuticals has been given orphan drug designation from the US Food and Drug Administration (FDA) for GLR2007 for the treatment of malignant ... Read More